Abilify Asimtufii® (aripiprazole) – New drug approval
April 28, 2023 - Otsuka and Lundbeck announced the FDA approval of Abilify Asimtufii (aripiprazole) extended-release injectable suspension, for the treatment of schizophrenia in adults and for maintenance monotherapy treatment of bipolar I disorder in adults.
Top